Replication Data for: Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya (doi:10.7910/DVN/Z8DRSK)

View:

Part 1: Document Description
Part 2: Study Description
Part 3: Data Files Description
Part 4: Variable Description
Part 5: Other Study-Related Materials
Entire Codebook

Replication Data for: Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya

doi:10.7910/DVN/Z8DRSK

Harvard Dataverse

2018-01-12

1

Nyiro, J.U.; Munywoki, P.K.; Nokes, D.J., 2018, "Replication Data for: Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya", https://doi.org/10.7910/DVN/Z8DRSK, Harvard Dataverse, V1, UNF:6:YPD4A23sNBfhF5XA8zCMCQ== [fileUNF]

Replication Data for: Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya

doi:10.7910/DVN/Z8DRSK

Nyiro, J.U. (KEMRI-Wellcome Trust Research programme, Kilifi, Kenya)

Munywoki, P.K. (KEMRI-Wellcome Trust Research programme, Kilifi, Kenya)

Nokes, D.J. (KEMRI-Wellcome Trust Research programme, Kilifi, Kenya; School of Life Sciences and WIDER, University of Warwick, Coventry, United Kingdom)

Mwango, L.M

102975

084633

Harvard Dataverse

Nyiro, J.U.

Munywoki, P.K.

Nokes, D.J.

Nyiro, J.U.

2018-01-09

https://doi.org/10.7910/DVN/Z8DRSK

Medicine, Health and Life Sciences

<p>Acute respiratory infection (ARI) is a leading cause of morbidity and mortality in children <5 years old worldwide [1], and respiratory syncytial virus (RSV) is the most important viral pathogen responsible for annual bronchiolitis and pneumonia epidemics in these young children [2–5]. Global estimates indicate that RSV may cause about 0.3 million deaths in young children per year and 99% of these occur in low-income countries[1].</p> <p>To date there are no licensed vaccines for prevention of RSV disease in infants and young children. Some candidate vaccines have shown promising results[6–8]. Most recently, an attenuated vaccine MEDI ΔM2-2, developed by the use of reverse genetics systems has been shown to be highly restricted in replication and more immunogenic in RSV seronegative children than the previous lead live attenuated RSV vaccine candidates [9]. As a result, these findings provide evidence of availability of a promising candidate vaccine for young children and infants in the near future.</p> <p>The primary target for RSV vaccination is children under 6 months of age; a group highly susceptible to severe RSV disease[10]. However, vaccination of this age group is complicated by the presence of maternal antibodies, among other factors[11]. Assuming the efficacy of a potential vaccine is significantly reduced if administered in the presence of maternal antibodies, it follows that the age of vaccination should be delayed. However, a majority of primary RSV infections are acquired early in life[12] and so delaying vaccination could result in missing out on a large proportion of preventable infections. As such a vaccination window or age should be established such that there is minimal maternal antibody interference and a majority of infections have not occurred.</p> <p>In this study we present the age-specific prevalence of antibodies to RSV from a rural community at the Kenyan coast. We then develop three nested catalytic models that explore different assumptions on the RSV specific antibody dynamics. Samples were selected randomly from pediatric admissions to a County hospital in coastal Kenya, and screened for antibodies to RSV by ELISA. The data from this study provides basic understanding on natural response to RSV infection and has a bearing on the optimal age of RSV vaccine delivery.</p>

2007-01-02-2010-12-31

Open Access

Related Datasets: https://doi.org/10.1371/journal.pone.0177803.s001 (XLS) <br> Additional information of the analysis: https://doi.org/10.1371/journal.pone.0177803.s002 (DOCX)

Publications based on this data collection should acknowledge this source by means of bibliographic citation. To ensure that such source attributions are captured for bibliographic utilities, citations must appear in footnotes or in the reference section of publications. The bibliographic citation for this data collection is: "Nyiro, J.U.; Munywoki, P.K.; Nokes, D.J., 2018, "Replication Data for: Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya", doi:10.7910/DVN/Z8DRSK, Harvard Dataverse,V1"

This data is made available under the Creative Commons Attribution 4.0 International (CC BY 4.0) - https://creativecommons.org/licenses/by/4.0/legalcode. Publications based on these data should acknowledge this source by means of bibliographic citations. For more information on these data, please contact the authors: Nyiro, J.U. (JNyiro@kemri-wellcome.org); Munywoki, P.K. (PMunywoki@kemri-wellcome.org); Nokes, D.J. (JNokes@kemri-wellcome.org) or the data governance office via this email address: dgc@kemri-wellcome.org

Additional information of the analysis: https://doi.org/10.1371/journal.pone.0177803.s002 (DOCX)

https://doi.org/10.1371/journal.pone.0177803.s001 (XLS)

Nyiro, J.U., Kombe, I.K., Sande, C.J., Kipkoech, J., Kiyuka, P.K., Onyango, C.O., Munywoki, P.K., Kinyanjui, T.M. and Nokes, D.J., 2017. Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya. PLoS One, 12(5), p.e0177803.

10.1371/journal.pone.0177803

Nyiro, J.U., Kombe, I.K., Sande, C.J., Kipkoech, J., Kiyuka, P.K., Onyango, C.O., Munywoki, P.K., Kinyanjui, T.M. and Nokes, D.J., 2017. Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya. PLoS One, 12(5), p.e0177803.

• Number of cases: 960

• No. of variables per record: 4

• Type of File: text/tab-separated-values

UNF:6:YPD4A23sNBfhF5XA8zCMCQ==

Raw Dataset (CSV)

• age_months - age_months
• LRTI_total - LRTI_total
• RSV - RSV
• rsv_av_logau - rsv_av_logau

f3099660 Location:

Summary Statistics: Min. 0.0; Valid 960.0; StDev 33.12151282540107; Mean 24.31297058242916; Max. 144.9856262

Variable Format: numeric

Notes: UNF:6:3ZUv4yGcFYEZd2RrHExyfg==

f3099660 Location:

Summary Statistics: StDev 0.48037159032326954; Min. 0.0; Mean 0.3604166666666674; Max. 1.0; Valid 960.0

Variable Format: numeric

Notes: UNF:6:cltUlOf/R1eto+wuUuLI3Q==

f3099660 Location:

Summary Statistics: Min. 0.0; Valid 960.0; Mean 0.06458333333333252; StDev 0.2459173062544982; Max. 1.0

Variable Format: numeric

Notes: UNF:6:PJq0hgEDf6vOpdb1kmhENw==

f3099660 Location:

Summary Statistics: Mean 1.886749479486458; Valid 960.0; Max. 3.815000057; StDev 0.7444960507588169; Min. 0.476000011;

Variable Format: numeric

Notes: UNF:6:K6v3TWrptGWpr9tC01+RXw==

Label:

ConfidenceInt2_2.m

Text:

m-file (MATLAB)

text/x-matlab

Label:

Main_results.m

Text:

m-file (MATLAB)

text/x-matlab

Label:

msirsir11_2.m

Text:

m-file (MATLAB)

text/plain; charset=US-ASCII

Label:

msirsir15.m

Text:

m-file (MATLAB)

text/plain; charset=US-ASCII

Label:

msirsirmax11_2.m

Text:

m-file (MATLAB)

text/plain; charset=US-ASCII

Label:

msirsirmax15.m

Text:

m-file (MATLAB)

text/plain; charset=US-ASCII

Label:

Nyiro_Kombe_RSV_age_seroprevalence_codebook.pdf

Text:

Variable Codebook / Data Dictionary

application/pdf

Label:

Nyiro_Kombe_RSV_age_seroprevalence_ReadmeFile.txt

Text:

Readme File

text/plain

Label:

Nyiro_Kombe_RSV_age_seroprevalence_Supplementary_Text.docx

application/vnd.openxmlformats-officedocument.wordprocessingml.document

Label:

Regroup.m

Text:

m-file (MATLAB)

text/plain; charset=US-ASCII